002030 達安基因
按盤價 
6.170 +0.070 (+1.148%)
6.170 +0.070 (+1.148%) | 2024/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 198,308 | -41.85% | 1,180,897 | 12,046,135 | 7,664,262 | 5,341,210 | |
| 減：營業總成本 | 207,952 | -37.30% | 1,133,441 | 5,191,468 | 3,600,398 | 2,713,117 | |
| 其中:營業成本 | 87,581 | -41.96% | 584,929 | 3,271,535 | 1,934,079 | 1,594,244 | |
| 財務費用 | (16,088) | 37.61% | (74,749) | (111,036) | (30,813) | 28,644 | |
| 資產減值損失 | 54 | -- | (262,754) | (681,999) | (19,243) | (9,121) | |
| 公允價值變動收益 | (365,573) | -1,650.73% | 435,691 | 82,321 | (83,779) | 286,228 | |
| 投資收益 | (22,096) | 68.59% | (26,247) | 271,184 | 219,125 | 150,160 | |
| 其中：對聯營企業和合營企業的投資收益 | (25,864) | 62.28% | (46,101) | 129,360 | 164,859 | 110,222 | |
| 營業利潤 | (433,307) | -957.64% | 121,622 | 6,329,254 | 4,125,397 | 2,940,089 | |
| 利潤總額 | (434,068) | -969.44% | 113,536 | 6,318,937 | 4,120,081 | 2,902,866 | |
| 減：所得稅費用 | (72,927) | -700.36% | 41,804 | 891,378 | 501,595 | 452,821 | |
| 淨利潤 | (361,141) | -1,055.96% | 71,732 | 5,427,558 | 3,618,487 | 2,450,045 | |
| 減：非控股權益 | 2,150 | 76.71% | (32,928) | 15,217 | 300 | 955 | |
| 股東淨利潤 | (363,291) | -1,093.65% | 104,660 | 5,412,341 | 3,618,187 | 2,449,090 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.259 | -1,091.95% | 0.075 | 3.857 | 2.578 | 1.745 | |
| 每股派息 (元) * | -- | -- | 0.015 | 1.750 | 1.110 | 0.550 | |
| 每股淨資產 (元) * | 6.069 | -24.88% | 6.327 | 8.052 | 5.238 | 4.866 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 16/08/2024 12:34 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
